SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios completion of the first German labeling and packaging run for ANKTIVA is driving attention, with traders viewing it as a tangible step toward European commercialization and potential international revenue. Bulls expect broader approvals and a short squeeze, while skeptics argue the rollouts financial impact remains unproven and cite cash burn, dilution, and continued volatility.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

Hawkish commentary from Fed official Kevin Warsh, including repeated references to inflation and possible rate hikes, has driven a broad selloff in fintech and other rate-sensitive stocks, with traders debating whether the move is macro-driven or amplified by options positioning. Bulls argue SoFis guidance already accounts for potential hikes and continue buying the dip, while bears cite its high rate sensitivity and weak price action.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Anticipation of upcoming earnings, amplified by traders focus on reports that Michael Burry increased his LULU position, is driving attention. Bulls cite the potential impact of tariff refunds, the incoming CEO and low valuation, while bears remain concerned about weak consumer demand, competition and slowing U.S. and China sales.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A disclosed bearish BMF Capital short report criticizing SELLASs REGAL Phase 3 design, statistical power, dilution and valuation triggered the selloff and dominated discussion. Traders are divided between viewing it as a self-interested hit piece with no new clinical evidence and worrying that the delayed 80th event, quiet period and pending REGAL topline results could signal unfavorable data.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

A strong quarterly earnings beat and better-than-expected outlook drove an initial surge in Affirm shares, while the sharp reversal drew debate over sell-the-news profit-taking, options-related trading, and broader rate concerns around the Feds Jackson Hole event. Bulls view the pullback as temporary despite solid growth, while bears see a recurring post-earnings fade and renewed credit-risk concerns.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of a potential Anthropic IPO is driving attention, with traders viewing DXYZ as a major pre-IPO proxy because of its Anthropic exposure and expecting a re-rating alongside an updated NAV. The bullish case is tempered by debate over stale NAV disclosures, dilution, and whether the Anthropic SPV structure is valid, contributing to significant volatility and skepticism.

Reading International, Inc. is an entertainment and real estate company, which engages in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through the Cinema Exhibition and Real Estate segments. The Cinema Exhibition segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, City Cinemas, 44 Union Square, and Liberty Theatres brands. The Real Estate segment consists of real estate development and the rental or licensing of retail, commercial and live theater assets. The company was founded by James J. Cotter Sr. in 1999 and is headquartered in New York, NY.

Reading International Inc - Ordinary Shares - Class B

A sharp move in Reading Internationals thinly traded Class B shares has focused attention on low-float, short-squeeze and buyout speculation, with traders citing volatility, trading halts and limited share availability. Some also point to a reported earnings turnaround and the companys real-estate assets, while others warn the move may be a momentum-driven pump with selling pressure and no confirmed new catalyst.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Renewed reports of a Qatari-backed Irth Capital take-private bid, supported by Papa Johns largest U.S. franchisee, are driving attention and fueling hopes for a premium acquisition and potential short covering. Traders remain divided, with bulls expecting a deal or activist pressure while skeptics cite weak same-store sales, debt, dividend suspension, and uncertainty over managements willingness to sell.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as investors react to a significant 20-year power agreement with Microsoft to supply natural gas for AI data centers, while also weighing broader energy sector volatility driven by geopolitical tensions and fluctuating oil supply. Community discussion is focused on the company's long-term cash flow strength, the strategic pivot toward powering AI infrastructure, and mixed sentiments regarding the impact of ongoing Middle East instability on oil production.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

FDA accelerated approval of TRUTAKNA (atacicept) for adults with IgA nephropathy is the main catalyst, shifting attention to Veras commercial launch and the upcoming kidney-function data. Traders are divided between viewing the approval and high short interest as supportive for a squeeze, and arguing that the muted reaction reflects sell-the-news behavior and competitive pressure from rival therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Orchid Pharma says NCLT dismisses DBS Bank lease rent claim with no impact on operations

Orchid Pharma Limited ( ($IN:ORCHPHARMA) ) has shared an announcement. Orchid Pharma has disclosed that the National Company Law Tribunal’s Chennai...

Orchid Pharma Limited - 2/18/2025

Orchid Pharma Limited - 2/18/2025. Country: India. Record Type: 483

From Generic Manufacturer to Global Innovator: How Orchid Pharma Is Fighting the Silent Pandemic

… landscape, scientists at Orchid Pharma Limited (OPL) in Chennai … can compete with global pharmaceutical giants changing the … helps preserve these crucial drugs , slowing the race between … . Currently, the global pharmaceutical industry depends heavily on …

Superbugs are rising. India’s scientists are fighting back

Big Pharma is vacating infectious diseases research to chase more lucrative segments like oncology and diabetes. This has left behind a gaping void. A set of Indian companies are diving in—Wockhardt, Orchid Pharma and Bugworks. A successful antibiotic drug can change their fortunes.

Breakdown Stocks: How to trade Orchid Pharma, Everest Industries and Jai Corp that hit a 52-week low?

Indian markets rebounded strongly on Tuesday, with the Sensex surging over 1,000 points and Nifty crossing 22,500, led by gains in capital goods, telecom, and oil & gas sectors.

Orchid Pharma shares in focus as U.S. FDA completes facility inspection

Orchid Pharma share price: Orchid Pharma's Alathur facility is the only U.S. FDA-approved manufacturing site in India for sterile cephalosporins, a group of antibiotics used to treat bacterial infections.

Market Update: 450 Smallcap 10-41% ,

Market Trend: - , . . , 9.4% , 8%, 7%, 6%, 5.7% 5.2% . Smallcap 10-41% , - . 450 10% 41% , . , 25% . NGL Fine Chem 41.31% NGL Fine Chem , (Veterinary Active Pharmaceutical Ingredients) (APIs) . . , - . Natco Pharma 32.99% Natco Pharma , () . - . Excel Industries 32.79% Excel Industries (Agrochemicals & Specialty Chemicals) . , . Orchid Pharma 32.67% Orchid Pharma , (Cephalosporins) . (R&D) . WPIL 32.25% WPIL . , . Tilaknagar Industries 30.8% Tilaknagar Industries , IMFL (Indian Made Foreign Liquor) . , , . Banco Products (India) 30.58% Banco Products . , . Senco Gold 28.21% Senco Gold , , . . Suyog Telematics 28.15% Suyog Telematics . , . . Concord Biotech 27.71% Concord Biotech . , , . Zaggle Prepaid Ocean Services 26.82% Zaggle Prepaid (FinTech) SaaS (Software-as-a-Service) , Prince Pipes & Fittings 25.62% Prince Pipes & Fittings . , - . Gensol Engineering 25.57% Gensol Engineering (Solar Energy) , (Solar EPC) . , . Lincoln Pharmaceuticals 25.27% Lincoln Pharmaceuticals , . , -, . Suraj Estate Developers 25.

Orchid Pharma Ltd. engages in the provision of development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. Its products include cardiovascular, anti-diabetic, neuropsychiatry, nutritional supplements, cephalosporins-orals, cephalosporins-injectables, veterinary products, and non-antibiotics. The company was founded by Kailasam Raghavendra Rao on July 1, 1992 and is headquartered in Narsinghpur, India.

Current Price	972.60
Prev Close	930.00
Open	931.90
Dividend Yield	0.00%
50-Day Moving Average	1,001.57
Beta	-0.05
Avg. Volume	289,641.22
PE Ratio	570.43

52-Week High	1,133.00
52-Week Low	480.00
Market Capitalization	47.13B
EPS (Annual)	4.05
Price to Book	3.88
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info